<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600169</url>
  </required_header>
  <id_info>
    <org_study_id>20150907</org_study_id>
    <nct_id>NCT02600169</nct_id>
  </id_info>
  <brief_title>Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab</brief_title>
  <official_title>Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a retrospective cohort study. A database will be created from the data
      available of all patients that have participate in the named patient program for
      pembrolizumab in the Netherlands. This database will be used for analysis of response markers
      and for an evaluation of adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a retrospective cohort study. A database will be created from the data
      available of all patients that have participate in the named patient program for
      pembrolizumab in the Netherlands. This database will be used for analysis of response markers
      and for an evaluation of adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early serum response markers</measure>
    <time_frame>up to day 126</time_frame>
    <description>Serum markers: S100B, LDH, white blood count differential neutrophils, monocytes, lymphocytes, eosinophils, basophils. Markers will be correlated to early response as measured by RECIST 1.1 criteria at week 12 and 18 of treatment with pembrolizumab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predicitve patient characteristics</measure>
    <time_frame>baseline</time_frame>
    <description>Patient characteristics: age, gender, WHO performance status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Predictive tumor characteristics</measure>
    <time_frame>baseline</time_frame>
    <description>Tumor characteristics: M-stage, presence of CNS metastases, mutation status, PD-L1 status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events of clinical interest will be collected and graded according to the CTCAE version 4.0 criteria</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival will be evaluated for all patients treated with pembrolizumab.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Patients treated with pemprolizumab</arm_group_label>
    <description>All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemprolizumab</intervention_name>
    <description>All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.</description>
    <arm_group_label>Patients treated with pemprolizumab</arm_group_label>
    <other_name>MK3475</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in this study have received treatment with pembrolizumab for the indication of
        an advanced melanoma.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        All patients that were eligible for treatment with pembrolizumab in the Named Patient
        Program in the Netherlands.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G.A.P. Hospers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G. A.P. Hospers, MD, PhD</last_name>
    <phone>+31 503612821</phone>
    <email>g.a.p.hospers@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>C. Bisschop, MD</last_name>
    <phone>+31 50 3616161</phone>
    <email>c.bisschop@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. A.P. Hospers, MD, PhD</last_name>
      <phone>+31 50 3612821</phone>
      <email>g.a.p.hospers@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>C. Bisschop, MD</last_name>
      <phone>+31 50 3612821</phone>
      <email>c.bisschop@umcg.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>G.A.P. Hospers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

